Results 31 to 40 of about 34,393 (185)
The Dumb ErbB Receptor Helps Healing [PDF]
Journal of Investigative Dermatology, 2007 ErbB3 receptor is a member of the epidermal growth factor (EGF) receptor (ErbB1) family. Okwueze et al. have transfected this receptor in a pig model of wounds and demonstrate that it accelerates the resurfacing of the wounds when combined with epiregulin or heparin-binding EGF. Currently, only hypotheses can be proposed to explain the observations.
openaire +3 more sources
PLoS ONE, 2008 BackgroundTamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. Its benefits in adjuvant treatment are well documented in controlled and randomized clinical studies, which have demonstrated an increase in ...
Valentina Folgiero +14 more
doaj +1 more source
Scientific Reports, 2017 Current pathophysiological models of schizophrenia focus on neurodevelopmental and immunological mechanisms. We investigated a molecular pathway traditionally linked to the neurodevelopmental hypothesis (neuregulin 1 - ErbB), and pathogen-associated ...
Szabolcs Kéri +2 more
doaj +1 more source
PLoS ONE, 2012 First-generation interaction maps of Src homology 2 (SH2) domains with receptor tyrosine kinase (RTK) phosphosites have previously been generated using protein microarray (PM) technologies.
Ronald J Hause +5 more
doaj +1 more source
Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tryosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4 [PDF]
Oncogene, 1997 Epiregulin is a member of the epidermal growth factor (EGF) family, and has certain characteristics that are different from that of EGF, including mitogenic responses and binding to EGF receptor (EGFR). Epiregulin may also have another cell surface receptor and/or induces different receptor heterodimerizations for intracellular signaling.
T, Komurasaki +3 more
openaire +2 more sources
Cell Death and Disease, 2022 Triple-negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of receptor tyrosine kinase ErbB-2/HER2.
Santiago Madera +18 more
doaj +1 more source
Ligand-induced ErbB receptor dimerization [PDF]
Experimental Cell Research, 2009 Structural studies have provided important new insights into how ligand binding promotes homodimerization and activation of the EGF receptor and the other members of the ErbB family of receptor tyrosine kinases. These structures have also suggested possible explanations for the unique properties of ErbB2, which has no known ligand and can cause cell ...
openaire +2 more sources
Analysis of ErbB Receptors in Pulmonary Carcinoid Tumors [PDF]
Clinical Cancer Research, 2009 AbstractPurpose: This study aimed to investigate the expression of the ErbB family of receptor tyrosine kinases in pulmonary typical carcinoid and atypical carcinoid tumors and to understand the role of epidermal growth factor receptor (EGFR) signaling in pulmonary carcinoid tumor proliferation.Experimental Design: Surgically resected typical carcinoid
Otis B, Rickman +6 more
openaire +2 more sources
Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition. [PDF]
PLoS ONE, 2012 Growth factors activating the ErbB receptors have been described in prostate tumors. The androgen dependent prostate cancer cell line, LNCaP, expresses the ErbB-1, ErbB-2 and ErbB-3 receptor tyrosine kinases.
Eran Schmukler +3 more
doaj +1 more source
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source